What NMD Pharma does

NMD Pharma is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of the skeletal muscle-specific ClC-1 chloride ion channel for the treatment of severe neuromuscular diseases. The company was founded in 2015 as a spin-out from Aarhus University, Denmark, building on more than 15 years of muscle physiology research into a proprietary ClC-1 inhibition platform that is designed to restore skeletal muscle activation in diseases where neuromuscular transmission is failing. Its lead candidate NMD670 is being evaluated in three parallel Phase 2 clinical trials in generalized myasthenia gravis, spinal muscular atrophy type 3, and Charcot-Marie-Tooth disease types 1 and 2, while a second ClC-1 inhibitor (ignaseclant) is in Phase 2a development for CMT and a third candidate (NMD1343) has entered Phase I.

The company leverages a world-leading muscle electrophysiology platform that combines in-depth know-how of muscle physiology, muscular disorders, small molecule modulators, enabling technologies, and in vivo pharmacology models. To date, NMD Pharma has secured FDA Orphan Drug Designation for NMD670 in both myasthenia gravis and Charcot-Marie-Tooth disease and FDA IND clearances for Phase 2 trials across SMA, gMG, and CMT. A team of 60+ employees is headquartered in Aarhus, Denmark, with secondary offices in Copenhagen and Cambridge, Massachusetts, supporting US clinical operations.

NMD Pharma is pre-revenue and has raised approximately €180 million from leading life sciences investors, including Jeito Capital (lead in both Series B rounds), INKEF Capital, Roche Venture Fund, Novo Holdings, and Lundbeckfonden BioCapital. Its go-to-market model is the standard biotech regulatory pathway: pursue FDA Orphan Drug Designation and expedited development, run Phase 2 and Phase 3 trials, and generate revenue through commercialization of approved drugs via traditional pharmaceutical distribution channels once clinical and regulatory milestones are achieved. The company collaborates with key opinion leaders, academic medical centers, and patient advocacy organizations to support clinical execution and patient access.

Name

NMD Pharma

Legal name

NMD Pharma A/S

Website

https://nmdpharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

NMD Pharma is a clinical-stage biotech developing first-in-class small molecule ClC-1 ion channel inhibitors to restore skeletal muscle activation in neuromuscular diseases, including myasthenia gravis, SMA, and Charcot-Marie-Tooth disease. Pre-revenue, headquartered in Aarhus, Denmark, with US operations in Boston.

Ownership category

akta.pro rank

Product category

Neuromuscular Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Neuromuscular disease therapeutics
• Small molecule drug discovery
• Ion channel inhibitors
• Clinical stage biotechnology
• Rare disease treatments

Headquarters

HQ city

Risskov

HQ country

Denmark

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company developing novel therapeutics for neuromuscular diseases. Revenue will be generated through sales of approved drugs upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

NMD Pharma discovers and develops first-in-class small molecule inhibitors of the skeletal muscle-specific ClC-1 chloride ion channel for the treatment of severe neuromuscular diseases. Its lead candidate NMD670 is being evaluated in three Phase 2 clinical trials for myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease, with a second pipeline asset ignaseclant in Phase 2a for CMT and NMD1343 in Phase 1.

Product overview

NMD Pharma is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The company's lead product NMD670 is a ClC-1 inhibitor being evaluated across three Phase 2 clinical studies for myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease. A second candidate, ignaseclant, is also in Phase 2a development for CMT. The company leverages a world-leading muscle electrophysiology platform built on over 15 years of muscle physiology research.

Differentiator

Problem solved

Functional benefit

Products and services

• NMD670 First-in-class small molecule inhibitor of the skeletal muscle-specific ClC-1 chloride ion channel being developed for the treatment of neuromuscular diseases including generalized myasthenia gravis, spinal muscular atrophy type 3, and Charcot-Marie-Tooth disease types 1 and 2. NMD670 enhances neuromuscular transmission and restores skeletal muscle function, with FDA Orphan Drug Designations granted for both gMG (September 2022) and CMT (January 2025).
• ignaseclant Second ClC-1 inhibitor molecule in NMD Pharma's pipeline being evaluated in the Phase 2a SYNAPSE-CMT clinical trial for Charcot-Marie-Tooth disease types 1 and 2. Treatment produced statistically significant improvements in hand grip strength and motor function in 81 adult CMT patients, with functional gains maintained beyond treatment discontinuation.
• NMD1343 Third drug candidate in NMD Pharma's pipeline, currently in Phase I safety, tolerability, and pharmacokinetics studies as a ClC-1 inhibitor small molecule therapy.

Quantifiable outcome

• Up to 50% of myasthenia gravis patients met pre-specified responder criterion with clinically significant improvements in Quantitative Myasthenia Gravis Score
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Aarhus UniversitycoreStrategic or Co-development Partner · 8 July 2021International collaboration for ESTABLISH study led by Prof. Dr. Henning Andersen. NMD Pharma founded as spin-off from Aarhus University in 2015 based on 15+ years of muscle physiology research.
• The Ohio State UniversitycoreStrategic or Co-development Partner · 8 July 2021Collaboration with The Ohio State University Wexner Medical Center for ESTABLISH study led by Prof. Dr. William David Arnold. Research collaboration on sarcopenia observational studies.
• Centre for Human Drug Research (CHDR)coreStrategic or Co-development Partner · 30 June 2021Clinical research institute in Leiden, Netherlands where Phase I/IIa clinical trial of NMD670 in myasthenia gravis was conducted. Specialized in cutting-edge early-stage clinical drug research.
• Hereditary Neuropathy Foundation (HNF)minorOthersPatient advocacy organization providing statement supporting NMD Pharma's FDA IND clearance for CMT trial. CEO Allison Moore commented on NMD Pharma's focus on developing treatments for multiple CMT subtypes.
• CMT Research Foundation (CMTRF)minorOthersPatient-led nonprofit focused on delivering treatments and cures for CMT. CEO Cleary Simpson provided statement supporting NMD Pharma's CMT program advancement to Phase 2.
• Charcot-Marie-Tooth Association (CMTA)minorOthersCommunity-focused nonprofit with mission to support CMT treatment development. Named NMD Pharma as Alliance Partner. CEO Sue Bruhn expressed support for FDA IND clearance.
• INCUBAminorOthersBusiness incubator in Aarhus where NMD Pharma moved its headquarters to support future growth. Provided startup ecosystem support and environment.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• argenx: argenx develops Vyvgart (efgartigimod), an FcRn antagonist approved for generalized myasthenia gravis. Directly competes with NMD Pharma in the MG space, although via a different mechanism (FcRn-mediated IgG reduction vs. ClC-1 muscle activation).
• Catalyst Pharmaceuticals: Catalyst Pharmaceuticals commercializes Firdapse for LEMS and is developing treatments for other neuromuscular disorders. Comparable as a smaller commercial-stage company focused on rare neuromuscular diseases.
• Ionis Pharmaceuticals: Ionis developed Spinraza (with Biogen) for SMA and has a pipeline of antisense oligonucleotides for neuromuscular and neurological diseases. Comparable as a clinical/commercial-stage rare neuromuscular disease therapeutics developer.
• PTC Therapeutics: PTC Therapeutics markets Translarna for Duchenne muscular dystrophy and has a pipeline in SMA and other neuromuscular disorders. Comparable as a mid-cap rare neuromuscular disease therapeutics company with multiple programs across genetic muscle disorders.

Broad incumbents

• UCB: UCB markets Rystiggo (rozanolixizumab) and zilbrysq (zilucoplan) for myasthenia gravis. Larger established pharma with overlapping MG assets and broader neurology portfolio including Cimzia and Briviact.
• Biogen: Biogen commercializes Spinraza for SMA (with Ionis) and has a broad neurology portfolio. Larger established biopharma with overlapping neuromuscular disease presence and far greater scale.
• Novartis: Novartis commercializes Zolgensma, the gene therapy for SMA, and has a broad neuromuscular and rare disease franchise. Operates as a broad incumbent with significant resources and global commercial reach.
• Sarepta Therapeutics: Sarepta commercializes Elevidys for Duchenne muscular dystrophy and other gene therapies for neuromuscular diseases. Larger commercial-stage neuromuscular company with overlapping indications (muscular dystrophy, CMT-adjacent).

Emerging players

• Scholar Rock: Scholar Rock is developing apitegromab for SMA, a Phase 3 asset targeting muscle growth via myostatin inhibition. Comparable as a clinical-stage biotech pursuing novel muscle-targeted mechanisms in neuromuscular disease.
• Pharvaris: Pharvaris is a clinical-stage biotech developing oral bradykinin B2 receptor antagonists for hereditary angioedema. Comparable as a small clinical-stage European-headquartered rare-disease biotech with novel oral small molecule approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nmdpharma
• Facebookfacebook.com/NMDPharma
• LinkedInlinkedin.com/company/nmdpharma
• Instagraminstagram.com/nmdpharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NMD Pharma